Accessibility The results are similar, and less than half the time is required for scoring. According to the OMERACT, face validity is the degree to which the instrument appears to match with the target domain, according to experts [18]. Disclosure statement: L.A. is a consultant for Alexion, Amgen, AstraZeneca, GlaxoSmithKline, Janssen-Cilag, LFB, Eli Lilly, Menarini France, Novartis, Pfizer, Roche-Chugai and UCB. , Dietzmann K
Neuropsychiatry OXFORD TEXTBOOKS IN PSYCHIATRY Oxford Textbook of Neuropsychiatry Edited by Niruj Agrawal, Rafey Faruqui, and Mayur Bodani Oxford Textbook of Psychiatry of Intellectual Disability Edited by Sabyasachi Bhaumik and Regi Alexander Oxford Textbook of Inpatient Psychiatry Edited by Alvaro Barrera, Caroline Attard, and Rob Chaplin Oxford Textbook of Attention . Please check for further notifications by email. , Socher SA
The Senior Lead will be responsible for: Managing end to end production, governance and controls of Derivatives Standardized and Advanced RWA, and SLE Actuals. , Block JA
Physician global assessments for disease activity in rheumatoid arthritis are all over the map! Higher disease activity is an important predictor of both organ damage and mortality [2] and the attainment of low disease activity is associated with a reduction in early damage [5, 6]. The interRR was assessed in seven studies [4, 10, 11, 36, 65, 68, 94], showing values ranging from 0.67 [68] to 0.96 [94]. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ system, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. [PDF] Use of Physician Global Assessment in systemic lupus , Giannakou I
Unable to load your collection due to an error, Unable to load your delegates due to an error. Some may be a consequence of therapy and others may be . , Schirmbeck LA
A 21-numbered circle visual analog scale (VAS) may be a desirable alternative to the traditional 10-cm horizontal line for pain and patient global estimate on a Multidimensional Health Assessment Questionnaire (MDHAQ). , Mokkink LB
inflammation (duration and severity of morning stiffness as measured by BASDAI). It was published in 1977 and was initially designed for the measurement of self-assessed pain in rheumatoid arthritis although it has since been used to evaluate RA more globally. Of note, the literature search revealed heterogeneous definitions of physician assessment of disease activity other than the PGA (physician global assessment [4, 70, 73], physician overall assessment [85]). Five studies have demonstrated good ICC values for reliability (all >0.60 and ranging up to 0.97). In this sense, criterion validity of PGA is satisfied when scores correlate with phenomena subsequently influenced by disease activity, such as quality of life measurements (Health-related Quality of Life, 36-item Short Form Health Survey, Functional Assessment of Chronic Illness TherapyFatigue score, Lupus Impact Tracker and LupusPRO), biomarker levels (complement fractions, ESR, autoantibodies), treatment variations and damage assessments (SDI). , Block JA
, Sato JO
Careers. Liang et al. Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. et al. Criterion validity also refers to the degree to which an instrument predicts aspects and phenomena occurring in the future [108]. Physician Global Assessment International Standardisation COnsensus in Reviews and case series with fewer than five patients were excluded. To increase its reliability, the PGA should be scored by a physician with significant expertise in SLE, with prior knowledge of laboratory results [112], considering the overall disease activity at the time of the visit and comparing it to the last visit in order to assess flares [9]. However, it is important to remember that not all clinical problems reported by a lupus patient are due to the disease. 2019ACREULAR . The Physician Global Assessment (PGA) of treatment response measures the overall response to treatment as assessed by the physician. PGA0.3. , Annapureddy N
, Burlingame RW
Akhter E
Correlations with other instruments measuring similar constructs should typically demonstrate a coefficient (r) 0.50 [106]. , Fortin PR
An international panel of 79 SLE experts participated in a three-round Delphi consensus process, in which 41 statements related to the PGA in SLE were . Jesus D
Thanou A
Cloud, mobility, security, and more. They participate in physiologic and inflammatory cascades and have become a major focus of research, yielding novel therapies for immune-mediated inflammatory diseases (IMID). , Urowitz MB. Elisabetta Chessa, Matteo Piga, Alberto Floris, Herv Devilliers, Alberto Cauli, Laurent Arnaud, Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties, Rheumatology, Volume 59, Issue 12, December 2020, Pages 36223632, https://doi.org/10.1093/rheumatology/keaa383. Federal government websites often end in .gov or .mil. Because of the complexity of SLE, the assessment of disease activity is particularly challenging [3]. , Bentow C
Convergent validity is fulfilled indirectly in studies where the PGA is used as the gold standard to assess the construct validity of other indices. , Khamashta MA
et al. In the second column, the definitions were reported according to the VAS used in the study. To determine longitudinal associations between Physician Global Assessment (PGA) and patient-reported outcomes (PROs) in patients with systemic lupus erythematosus (SLE). However, no precise guidelines exist regarding the optimal use of the PGA in SLE, such as the adequate length of the VAS, the presence of anchored values, the incorporation of laboratory data and the time frame of assessment. (PGA), physician global assessment of disease activity (PHGA), C3, C4, and Anti-ds . , Nguyen SC
, Gladman DD. Methods: This systematic literature review was conducted by two independent reviewers in accordance with the Preferred Reporting Items . Disclaimer. , Ding HH
However, the PGA allows for the measurement of disease activity in a global way (content validity). Frontiers | Cutaneous lupus erythematosus disease assessment et al. Over the years, PGA-IGA scales were modified for the purpose of clinical settings and thus present a diversity in the number of response options (4 to 10 points), the response options label and the . Physician's Global Assessment (PGA) score 1.0 on a 0 to 3 visual analog scale. , Mina R
, Kharboutli M
Genetic linkage has related dysfunction of . The aim of this systematic literature review is to describe and analyse the psychometric properties of the PGA. government site. Content validity. , Shea BJ
et al. Patient global assessment in measuring disease activity in rheumatoid Methods Exagen Diagnostics Inc (XGN) - Product Pipeline Analysis, 2022 Update The aim of this systematic literature review (SLR) is to describe and analyse the psychometric properties of PGA. et al. , Giangreco D
et al. allergy hx phenothiazines, cns depressants and stimulants withheld 48 hours prior. The patients were diagnosed as having the following disorders: scleroderma (n = 27), dermatomyositis (n = 11), systemic lupus erythematosus (SLE) (n = 22), MCTD (n = 8), and RP without evidence of underlying CTD (n = 38). [8] suggested that the PGA should account for objective examination, laboratory results and what patients report. Enocsson H
Physician global assessment in systemic lupus erythematosus: Can we Physician global assessment in systemic lupus erythematosus: can we , ODell JR
Please enable it to take advantage of the complete set of features! Few studies reported on whether serological activity should be incorporated in the PGA. , Hennis A. Jesus D
Changes in the PGA correlated with changes of other disease activity indices (SLEDAI, SLAM, LAI, patient global assessment), laboratory exams (ESR), patient-reported outcomes (Lupus Impact Tracker) [23, 50, 58, 77, 78, 81, 83] and response to treatment [4]. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus and Lupus Nephritis - Epidemiology Thank you for submitting a comment on this article. The Physician Global Assessment (PGA) is a visual analogue score that reflects the clinicians judgement of overall SLE disease activity. Franklyn K
2014 Sep-Oct;10(5):309-20. doi: 10.1016/j.reuma.2014.01.012. , Gallacher AE
, Merrill JT. , Ibaez D
Mina R
, Buyon J
The sensitivity to change was estimated to be the smallest for the SLEDAI; the standardized response means were 0.48 when the physician global assessment was used as the standard and 0.01 when the patient global assessment was used . At least 1 issue from each virtual tour. All articles published through 1 July 2019 in PubMed were screened, with no limitation on year of publication, language or patients age. , Costenbader K
[2, 21, 24] recommended PGA assessment prior to reviewing serological data, based only on the clinical visit. et al. PGA - Lupus Research No study has evaluated the correlation of PGA with damage measures. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. disease activity in SLE, with the Physician Global Assessment (PGA) being the only one included in the updated EULAR recommendations for the management of SLE.11. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide, This PDF is available to Subscribers Only. et al. Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease (ARD) characterized by flares and remissions. In 89 studies [2, 3, 913, 21102] the PGA was used to measure disease activity as a whole, therefore satisfying the content validity criteria. , Rodrigues M
, Magder LS
Responsiveness. Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring. Navarra SV
Moreover, there is uncertainty as to whether the best timing of assessment is prior to or after reviewing laboratory exams [26]. , Piette EW
The 4-point PGA (0, no flare; 1, mild; 2, moderate; 3, severe) showed the lowest IRR in assessing flare (ICC=0.18) compared with the BILAG-2004 (ICC=0.54) and SFI (ICC=0.21) [65]. Nevertheless, despite the fact that the PGA was considered the reference in 39 studies involving other indices, it was used as the sole instrument in only 2 of them. et al. , Smiley A. Askanase AD
Importance: In dermatology, the development of objective, standardized quality measures that can be used in a clinical setting is important to be able to respond to the needs of payers and credentialing and licensure bodies and to demonstrate dermatologic value. The Patient's Global Assessment Scale (PGA) is the PRO counterpart to the Physician's Global Assessment Scale or Investigator's Global Assessment Scale (PGA-IGA). , Chizzolini C
'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. The company serves physicians and patients. The last EULAR/ACR recommendations recommended use of the PGA in the routine monitoring of SLE [16]. Ruiz-Irastorza G
Epub 2014 Apr 11. Clipboard, Search History, and several other advanced features are temporarily unavailable. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual, The systemic lupus activity measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus, Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests, Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50, Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation, Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months, Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial, Psychological distress and changes in the activity of systemic lupus erythematosus, The rating scale preference measure as an evaluative measure in systemic lupus erythematosus, Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus, Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months, Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus, Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006, Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale, Autoantibodies against albumin in patients with systemic lupus erythematosus, Association of depression with socioeconomic status, anticardiolipin antibodies, and organ damage in patients with systemic lupus erythematosus: results from the KORNET registry, Placebo-controlled randomized clinical trial of fish oils impact on fatigue, quality of life, and disease activity in systemic lupus erythematosus, Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus, Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis, Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity, Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus, Turkish LupusPRO: cross-cultural validation study for lupus, Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity, The TNF locus is altered in monocytes from patients with systemic lupus erythematosus, Effect of pregnancy on disease flares in patients with systemic lupus erythematosus, Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience, Morbidity of systemic lupus erythematosus: role of race and socioeconomic status, Classification and definition of major flares in SLE clinical trials, Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study, COSMIN guideline for systematic reviews of patient-reported outcome measures, Validity and reliability in social science research, Understanding the minimum clinically important difference: a review of concepts and methods, Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research, Minimum important difference between patients with rheumatoid arthritis: the patients perspective, Responsiveness and sensitivity to change of SLE disease activity measures, The Author(s) 2020. Objective Existing methods for grading lupus flares or improvement require definition-based thresholds as increments of change. The aim of this systematic literature review is to describe and analyse the . Petri M
, Altman DG
SELENA SLEDAI4. This potentially disfiguring disease can have significant impact on patient's quality of life (QoL) and is often refractory to many first- and second-line therapies. Physician's global assessment is often useful in SLE - ResearchGate , Sjwall C
Physician's Global Assessment Scale (PGA) or Investigator's Global Assessment Scale (IGA) measures disease status in a broad range of diseases. Chaigne B
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease that can occur with or without systemic lupus erythematosus (SLE). For permissions, please email: journals.permissions@oup.com, This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (. All articles published through 1 July 2019 in PubMed were screened, with no limitation on year of publication, language or patients' age. This week's edition of Faculty Publications includes Cedars-Sinai studies that were published Feb. 23-March 2. Ensure second line of defense Derivatives RWA reviews are performed consistently and . Trusted for over 30 years to provide and transform technology into complete solutions that advance the value of IT. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases Systemic Lupus Erythematosus (SLE) Treatment & Management - Medscape Copay AG
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) - Full may be asked to hyperventilate 3-4 min and watch a bright flashing light. The aim of this systematic literature review is to describe and analyse the psychometric properties of the PGA. Forbess LJ
In support of its face validity, the PGA was used to define the disease activity score in all 91 studies retrieved by the literature search, having a role as an outcome measure as well as a comparator to assess the validity of other indices. [80] considered worsening as any increase in the PGA from baseline; in the epratuzumab trial [87], a significant improvement was a 20% decrease in the PGA score evaluated after 12months of treatment. Supervise the development of junior medical affairs staff . , Jolly M. Mok CC
Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index, Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial, Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus, Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity, Characterization of clinical photosensitivity in cutaneous lupus erythematosus, Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus, Depressive symptoms and associated factors in systemic lupus erythematosus, Validation of the Portuguese simple measure of impact of lupus erythematosus in youngsters (SMILEY) in Brazil, Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers, Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus, An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA, Noncalcified coronary plaque in systemic lupus erythematosus, Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus, Validity and reliability of lupus activity measures in the routine clinic setting, Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting.